BioNTech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

BioNTech wird ein jährliches Gewinn- und Umsatzwachstum von 12.4% bzw. 3.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -2% betragen.

Wichtige Informationen

12.4%

Wachstumsrate der Gewinne

10.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	31.9%
Wachstumsrate der Einnahmen	3.4%
Zukünftige Eigenkapitalrendite	-2.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BOVESPA:B1NT34 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,599	-787	-1,021	-1,024	14
12/31/2025	2,602	-813	179	-601	19
12/31/2024	2,616	-765	468	975	17
9/30/2024	3,040	-467	971	1,522	N/A
6/30/2024	2,691	-504	2,352	2,972	N/A
3/31/2024	2,730	113	4,944	5,732	N/A
12/31/2023	3,819	930	4,666	5,371	N/A
9/30/2023	6,618	2,751	4,690	5,350	N/A
6/30/2023	9,184	4,375	8,726	9,317	N/A
3/31/2023	12,213	6,238	8,493	8,850	N/A
12/31/2022	17,311	9,434	13,214	13,577	N/A
9/30/2022	18,565	10,322	12,277	12,549	N/A
6/30/2022	21,191	11,748	9,040	9,271	N/A
3/31/2022	23,303	12,863	5,066	5,251	N/A
12/31/2021	18,977	10,293	736	890	N/A
9/30/2021	13,790	7,493	1,198	1,338	N/A
6/30/2021	7,770	4,072	-474	-355	N/A
3/31/2021	2,503	1,197	-376	-270	N/A
12/31/2020	482	15	-99	-13	N/A
9/30/2020	165	-410	-382	-326	N/A
6/30/2020	126	-230	-239	-183	N/A
3/31/2020	110	-192	-268	-222	N/A
12/31/2019	109	-179	-270	-198	N/A
9/30/2019	144	-122	-220	-138	N/A
6/30/2019	136	-116	-142	-75	N/A
3/31/2019	132	-77	-136	-55	N/A
12/31/2018	128	-48	-126	-59	N/A
12/31/2017	62	-86	N/A	-53	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: B1NT34 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: B1NT34 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: B1NT34 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: B1NT34Die Einnahmen des Unternehmens (3.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt BR (7.4% pro Jahr).

Hohe Wachstumseinnahmen: B1NT34Die Einnahmen des Unternehmens (3.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: B1NT34 wird voraussichtlich in 3 Jahren unrentabel sein.

BioNTech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

BioNTech SE Provides Revenue Guidance for the Full Year 2023

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

BioNTech SE Provides Revenue Guidance for the Full Year 2023

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union

Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken